Who we are and why Semaglutides exists

Why this site exists

Try searching for straightforward answers about GLP-1 medications and you will mostly find drugmaker pages, telehealth sellers and investor news. None of these answer the question you actually typed. Semaglutides exists to fix that: we answer the question you came with, show where each answer came from, and say when it was last checked.

What we cover

We cover every FDA-approved GLP-1 medication and the ones still in development. That includes semaglutide sold as Ozempic, Wegovy and Rybelsus; tirzepatide sold as Mounjaro and Zepbound; orforglipron, expected as Foundayo; and liraglutide sold as Saxenda, Victoza and generics. We also cover dulaglutide (Trulicity) and older drugs in the class. Our articles explain how these drugs work, what they cost, insurance coverage, clinical trials, label warnings, lawsuits, compounding and telehealth, plus a weekly news roundup.

How we work

Every article is built on primary sources: FDA labels and approval letters, ClinicalTrials.gov, peer-reviewed journals, company filings and court dockets. Each article carries a last-verified date and links to the sources behind it. Prices are re-checked at the seller, not copied from old articles. Where sources disagree, we say so plainly. You can read more in the editorial policy.

What we are not

We are not doctors, and nothing here is medical advice. We never tell you whether to take a drug or at what dose; those decisions belong with you and your clinician. We are not affiliated with Novo Nordisk, Eli Lilly or any pharmacy or telehealth company. Some telehealth links on the site are affiliate links, which is explained in the affiliate disclosure.

Corrections

If you spot an error, tell us through the contact page. We fix mistakes promptly and note the correction on the page.